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Using Drosophila behavioral assays 
to characterize terebrid venom-
peptide bioactivity
Anders Eriksson1, Prachi Anand2,3, Juliette Gorson2,3,4,5, Corina Grijuc2, Elina Hadelia2, 
James C. Stewart1, Mandë Holford  2,3,4,5,6 & Adam Claridge-Chang  1,7,8
The number of newly discovered peptides from the transcriptomes and proteomes of animal venom 
arsenals is rapidly increasing, resulting in an abundance of uncharacterized peptides. There is a pressing 
need for a systematic, cost effective, and scalable approach to identify physiological effects of venom 
peptides. To address this discovery-to-function gap, we developed a sequence driven:activity-based 
hybrid approach for screening venom peptides that is amenable to large-venom peptide libraries with 
minimal amounts of peptide. Using this approach, we characterized the physiological and behavioral 
phenotypes of two peptides from the venom of predatory terebrid marine snails, teretoxins Tv1 from 
Terebra variegata and Tsu1.1 from Terebra subulata. Our results indicate that Tv1 and Tsu1.1 have 
distinct bioactivity. Tv1 (100 µM) had an antinociceptive effect in adult Drosophila using a thermal 
nociception assay to measure heat avoidance. Alternatively, Tsu1.1 (100 µM) increased food intake. 
These findings describe the first functional bioactivity of terebrid venom peptides in relation to pain and 
diet and indicate that Tv1 and Tsu1.1 may, respectively, act as antinociceptive and orexigenic agents. 
Tv1 and Tsu1.1 are distinct from previously identified venom peptides, expanding the toolkit of peptides 
that can potentially be used to investigate the physiological mechanisms of pain and diet.
Venomous animals use their expansive venom arsenal to disrupt the physiology of other animals for both defen-
sive and predatory purposes. Due to the energetic cost of venom and the need for a fast-acting biological effect, 
venoms have evolved into cocktails of molecules with potent neurotoxic, haemophilic, and cytotoxic activities1. 
Specifically, venoms contain numerous, diverse peptides, many with highly specific bioactive properties that 
have proven useful as pharmacological therapeutics2–4. Currently, six venom-derived peptides are commer-
cially available drugs: ziconotide for pain5; exenatide for diabetes6; bivalirudin for anticoagulation7; captopril 
for hypertension8; and eptifibatide and tirofiban for coronary syndrome9. Venom-peptide research and drug 
discovery has increased exponentially with the advance of genomic–transcriptomic sequencing and proteomic 
mass-spectrometry10. However, translating newly discovered venom peptides into commercial therapeutics is 
challenging11. A variety of high-throughput electrophysiology, fluorescence, and radioactivity-based bioassays 
have been used to accelerate characterization of novel venom peptides12. Lacking from these is the ability to effi-
ciently characterize the physiological properties of the enormous diversity of venom peptides being identified. 
There is a need for new whole-animal in vivo methods that are applicable to scant quantities of venom peptides.
A striking example of the discovery-to-function gap in venom peptides is the identification and characteriza-
tion of peptides from marine snail venom. Predatory marine snails of the conoidean family, which includes cone 
snails (Conidae), terebrids (Terebridae), and turrids (Turridae), use venom peptides to prey on fish, worms, and 
other mollusks6,11,13. Cone snail venom peptides have shown remarkable selectivity for their molecular target, 
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ion channels and receptors14–16. Additionally, the compact size of conoidean venom peptides and their enhanced 
disulfide-bridged stability make them good candidates for pharmaceutical drug discovery and development17,18. 
There are over 15,000 species of conoideans, with an estimated venom-peptide reservoir of over a million com-
pounds19. However, less than 2% of conoidean venom peptides have been functionally characterized to date. 
Originally identified with assays in mice, Prialt (ziconotide) is the first conoidean venom drug, and it is used to 
treat chronic pain in HIV and cancer patients5,20. Ziconotide is chemically identical to the naturally occurring 
Conus magus peptide (MVIIA), and has illuminated a new molecular target for treating pain, namely N-type cal-
cium channels21,22. Ziconotide’s success has peaked the interest of pharmaceutical companies and there are several 
other cone snail venom peptides, conotoxins, in various stages of pharmaceutical drug development5,23–27. Given 
this, devising new cost-effective strategies to identify the bioactivities of snail-venom peptides could advance 
their use as biomedical physiological tools and development as drug candidates.
While conotoxins have received a lot of attention, the venom peptides from terebrid snails are less studied, 
representing an untapped resource. Terebrid transcriptomes and proteomic data reveal that similar to conotoxins, 
the venom peptides from terebrid snails, teretoxins, are highly structured and disulfide-rich- two features that 
benefit stability and pharmacokinetics28–30. However, it is important to note that while evolutionary similar, tere-
toxins and conotoxins differ in size, structural integrity and complexity, suggesting that they may have different 
molecular applications29. The potential of novel attributes of teretoxins for combating human disease and disorder 
demands efficient strategies to characterize these promising bioactive peptides17,31.
Pain and obesity are two major therapeutic areas for which an improved comprehensive pipeline that includes 
high-throughput physiological screening of teretoxin venom peptides could have an impact. In the U.S., the 
over-prescription of opioid pain medications has led to an epidemic of addiction and overdose for which treat-
ment remains elusive32,33. Remarkably, a potential solution to non-addictive pain therapies is the snail venom 
drug ziconotide. As ziconotide’s molecular site of action is N-type calcium channels and not opioid receptors, it is 
not addictive34. However, ziconotide does not cross the blood brain barrier and has to be delivered to the central 
nervous system via intrathecal injection, an invasive delivery method that limits its use35,36. Even with its limi-
tations, ziconotide is a paradigm shifting breakthrough that demonstrates there is an alternative non-addictive 
strategy for treating pain. As a result, here we examined teretoxins to identify new snail venom peptides that may 
have nociceptive properties and are peripherally active.
Similar to the upward trend in pain treatment, in the past 30 years the prevalence of obesity has reached 
epidemic proportions where the morbid obesity rates continue to rise37. Obesity is recognized as a major public 
health concern and is associated with numerous complications such as diabetes, cardiovascular diseases and 
various forms of cancer38–40. Obesity is a complex disorder caused by an imbalance between energy intake and 
the expenditure and the interaction between predisposing genetic and environmental factors41–43. Several pepti-
dergic systems within the central nervous system and the periphery are known to regulate energy homeostasis. 
However, the specific gene-gene and gene-environment interactions involved in this process remain unclear. A 
proposed treatment to combat obesity is being able to restore the energy homeostasis as a result of a dysregulation 
in the peptidergic system44. However, despite several efforts, the cause of obesity still remains inconclusive and the 
only effective treatment against obesity currently is gastric bypass surgery45. New compounds that can be used to 
investigate the cellular physiology of pain and obesity are needed in order to develop effective treatment.
In the search for new bioactive compounds that may be effective against pain and diet, we developed a phys-
iological approach using vinegar flies (Drosophila melanogaster) to screen biologically active teretoxin peptides. 
Flies are abundant, affordable, and amenable to automated behavioral testing, making them suitable for test-
ing venom-peptide bioactivity. Drosophila has been successfully used for drug screening in a number of exam-
ples: multiple endocrine neoplasia type 246, fragile X syndrome47, epithelial malignant growth48, intestinal stem 
cell-derived tumors49, combinatorial therapy50, and life span51. We focused on fly thermosensation and feeding, 
behaviors that have been used to model pain and obesity. Our approach uses in vivo pain and diet fly assays 
to characterize venom peptides from terebrid snails (Fig. 1). The strategy requires minimal amounts of venom 
peptide, by using a genetically tractable small-animal model. To establish the viability of this approach, we used 
several fly assays to characterize two teretoxins: Tv1 from Terebra variegata and Tsu1.1 from Terebra subulata. 
The two peptides had distinct properties: Tv1 displayed reduced avoidance towards noxious heat while, Tsu1.1 
increased the number of feeding bouts. The disparate bioactivity of Tv1 and Tsu1.1 supports the robust nature 
of our systematic fly behavioral assays for identifying new venom peptides that may have therapeutic relevance.
Results
Tsu1.1 is a novel teretoxin peptide. We used a bioinformatic pipeline to sequence, assemble and search 
the Terebra subulata venom-gland transcriptome for novel-peptide candidates (Fig. 2A). One of these candidates 
was a sequence with 21 amino acid residues (SAVEECCENPVCKHTSGCPTT), which we called Terebra sub-
ulata teretoxin 1.1 (Tsu1.1) (Fig. 2B). We compared Tsu1.1 with another peptide, Terebra variegata teretoxin 1 
(Tv1) which was previously characerized in the Holford group52. Teretoxins Tv1 and Tsu1.1 have distinct cysteine 
frameworks, a feature that is used to group conotoxins into functional groups, which suggests they might have 
different molecular targets31,53. Tv1 is arranged CC-C-C-CC (Framework III) while Tsu1.1 is arranged CC-C-C 
(Framework I) (Fig. 2C). In cone snails, Framework III conotoxins are in the M superfamily, a group of peptides 
that target either sodium (Na+) or potassium (K+) channels54. By contrast, Framework I conotoxins are in the A 
superfamily, which target either adrenergic receptors or nicotinic acetylcholine receptors (nAChR)54. An align-
ment of Tv1 and Tsu1.1 with known conotoxins confirms that, beyond their cysteine scaffold, and a conserved 
proline residue in Tsu1.1, Tv1 and Tsu1.1 are not homologous to members of their respective conotoxin super-
families and are distinct from known conotoxins (Fig. 2C)52.
www.nature.com/scientificreports/
3Scientific REPORTS |  (2018) 8:15276  | DOI:10.1038/s41598-018-33215-2
Tv1 and Tsu1.1 have minimal effects on mortality. We comparatively examined the bioactivity of 
Tsu1.1 and Tv1 teretoxin peptides. In order to investigate the physiological activity of the two peptides, we deter-
mined the levels at which the two peptides had lethal toxicity. Initial concentration was decided based on previous 
studies investigating the bioactivity of Tv1 in polychaete worms, where it was found that Tv1 caused a partial 
paralysis at a concentration of 20 μM52. However, an initial test with injections of 100 µM peptide (the highest 
dosage tested) found that neither peptide had major mortality effects in flies (Fig. S1A,B). Based on these results, 
we used injections of either 100 µM or 20 µM in subsequent experiments to explore Tv1 and Tsu1.1’s non-lethal 
bioactivities.
Tsu1.1 injections induce mild hypoactivity. While Tv1 had only trivial effects on fly activity, Tsu1.1 
injections had noticeable, though small, effects on multi-day daytime and nighttime activity (Fig. 3A,C). Over 













Figure 1. Schematic sequence-driven activity-based assay used to screen for teretoxin function. Venom glands 
are dissected from terebrids in the field. RNA is extracted in the lab and sequenced using next-generation 
sequencing. Transcriptomic data are assembled and searched for peptide candidates. Selected peptides are 
chemically synthesized, oxidized and injected into flies. Bioactivity is measured in several behavioral assays.
www.nature.com/scientificreports/
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than controls during the daytime (Fig. 3B), or a ∆distance of −226.93 mm ([95 CI −472.1, 29.29], g = −0.34, 
P = 0.04) (Fig. 3B). We investigated if the Tsu1.1 effect was associated with functional motor deficits using a 
climbing assay55. Upon injection with Tsu1.1, the flies exhibited only small or negligible differences in climbing 
index (Fig. 3C,D); this result suggests that Tsu1.1 does not diminish motor coordination.
Injection of Tv1 reduces heat avoidance. Teretoxin Tv1 has the same cysteine framework as known 
M superfamily conotoxins, members which have been characterized for targeting voltage-gated sodium chan-
nel (VGSC) subtypes NaV1.8 and NaV 1.9. These channels have been associated with controlling neuropathic 
pain56–58, and some M-superfamily peptides are potential antinociceptives14,16. Based on its cysteine-framework 
similarity to M-superfamily conotoxins, we examined if Tv1 had antinociceptive activity. We used an assay that 
measures Drosophila heat avoidance, that has been applied as a model of acute pain59. The assay monitors innate 
avoidance of noxious (46 °C) surfaces (Fig. 4A). The heat-avoidance assay was performed on flies injected with 
100 µM of Tv1 and Tsu1.1, and analyzed at 1 and 2 h time intervals after injection). One hour after injection, con-
trol flies injected with PBS had a heat avoidance of 70.9 [95 CI 65.4, 76.4]; Tv1-injected flies exhibited a markedly 
reduced avoidance response of 58.6 [95 CI 53.0, 64.2]. This represents a 12.33% reduction in avoidance ([95 CI 
−20.31, −4.39], g = −1.02, p = 0.005) after one hour; in terms of standardized effect sizes, this is a large effect60. 
Figure 2. Comparison of Tv1 and Tsu1.1 teretoxins. (A) The bioinformatic pipeline used to identify Tsu1.1. The 
orange box indicates the initial steps to generate reads through next-generation sequencing (NGS), the green 
shows the process to assemble the terebrid venom gland transcriptome, and the purple represents the final steps 
that lead to the discovery of teretoxins. (B) Shell images of Terebra variegata (left) and Terebra subulata (right), 
scale bar represents ~1 cm, followed by the sequence of each venom peptide, with cysteines highlighted in red, 
followed by the NMR structure of Tv146 and the predicted I-TASSER structure of Tsu1.1. (C) An alignment 
of Tv1 and conotoxins in the M-superfamily, followed by an alignment of Tsu1.1 and conotoxins in the 
A-superfamily. Green represents shared amino acids, while red represents shared cysteine framework.
www.nature.com/scientificreports/
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By the second hour, this response diminished to −4.97% ([95 CI −14.34, 4.7], g = −0.43, p = 0.33) (Fig. 4B). 
Tsu1.1 injected flies displayed heat avoidance that was similar to controls: 70.5% ([95 CI 65.5, 75.5]), or an avoid-
ance change of −2.3% ([95 CI −10.4, 5.8], g = −0.26, p = 0.58 v). These findings indicate that Tv1 reduces fly 
sensitivity to noxious heat.
Tsu1.1 administration increases food intake. Feeding and foraging behaviors strongly rely on a neu-
ronal and endocrinological connectivity through the gut–brain axis that also includes a peripheral regulation61–63. 
Thus, while we do not know whether teretoxins Tv1 and Tsu1.1 can cross the fly blood-brain barrier, the injected 
peptides could affect feeding via peripheral systems. Consequently, we assayed feedings over a 6 h time period 
using capillary-feeder assay64 that was adapted for video tracking of single-fly feeding64. In the Tv1 experiment, 
almost no difference in food intake was seen after injection and food intake decreased only −6.13 nl ([95 CI 
−23.10, 35.08], g = −0.07, P = 0.7) (Fig. 5E). In the Tsu1.1 experiment, while control flies injected with PBS drank 
an average of 214.0 nl [95 CI 180.12, 247,88], the Tsu1.1 injected flies drank 307.4 nl [95 CI 270, 344.8], 46% more 
liquid, an increase of +93.34 nl [95 CI 41.61, 141.485], g = + 0.55, P = 0.0002 (Fig. 5A).
Tsu1.1 increases meal frequency. To determine the behavior that produces the increased consumption, 
we examined the aspects of foraging behaviour (Fig. 5B). Consummatory behaviors in individual flies were ana-
lyzed over a 6 h period, allowing us to determine three additional feeding parameters: number of meals, the 
average meal size, and the meal duration (Fig. 5B–D). Injection of Tv1 had no effect on any of the parameters 
analyzed (Fig. 5E–H). However, Tsu1.1 injection elicited a increase in meal count: while control flies had 31.56 
meals per fly [95 CI 27.16, 35.96], flies injected with Tsu1.1 consumed 40.20 meals [95 CI 36.64, 43.76]. This was 
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Figure 3. Effects of Tv1 and Tsu1.1 on activity and motor coordination of male Drosophila. Activity was 
recorded for five consecutive days using automated video tracking and measured as the distance travelled per 
hour (mm/h/fly). Controls were maintained during the same conditions as the teretoxin-injected flies with 
the only difference that they were injected with PBS. (A) Activity assay of Tsu1.1. (B) Activity assay of Tv1. 
(C) Climbing index measured the short term effects of the toxins as well as possible disruptions in their motor 
coordination. The climbing assays of Tsu1.1 revealed only trivial effects on climbing ability. (D) Climbing assay 
of Tv1, all at 20 μM and 100 μM. All error bars represent 95% CI. The numbers indicated below each bar denote 
the standardized effect size (g). The climbing index was done with at least 15–20 male flies in each vial. Control 
data are depicted with grey dots, and teretoxin injected-fly data with orange dots.
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duration was also measured, both of which showed very small increases (Fig. 5C, D). Thus, the increased feed 
volume appears to arise largely as a result of an increased number of meals, with very minor contributions from 
increased meal duration and volume.
Tsu1.1





























Hedges’ g -1.02 -0.43
15 15



































Figure 4. Thermal nociception in adult Drosophila is diminished by Tv1. A thermal heat assay used to measure 
the antinociceptive effect of Tsu1.1 and Tv1 on adult flies. (A) Schematic representation of the assay measuring 
thermal nociception. The assay measures the avoidance from a noxious (46 °C) surface. (B) Injection with the 
higher concentration of Tv1 produced a large reduction in heat avoidance in the first hour: ∆ = −12.33% [95 CI 
−20.31, −4.39], g = −1.02, p = 0.005, N = 15. Hedges’ g is a standardized effect size. (C) Avoidance behavior in 
flies injected with two different concentrations of Tsu1.1 resulted in the control flies and the experimental flies 
displaying a similar heat avoidance. Control data are depicted in grey dots, and teretoxin injected-fly data in 
orange.
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Discussion
This work demonstrates the potential of Drosophila behavioral assays to analyze the physiological bioactivity of 
venom peptides. Specifically, we characterized the physiological effects of two teretoxins, Tv1 and Tsu1.1 from 
Terebra variegata and Terebra subulata respectively on thermosensation and feeding, behaviors that have been 
used to model pain and obesity. Pain and diet-related disorders are two areas for which new bioactive compounds 
are needed to advance therapeutic development.
Previously, Tv1 injected into Nereis virens, a polychaete worm, has been shown to induce partial paralysis52. 
This effect was absent in Drosophila (Fig. 3A, C), suggesting that the Tv1 may bind to targets which are not 
conserved between polychaetes and insect. However, our findings did show that injected Tv1 reduces fly heat 
avoidance (Fig. 4). This is the first demonstration that teretoxins can have an antinociceptive effect. A possible 
mechanism of action for Tv1-induced antinociception in flies is by modulation of TRP (Transient Receptor 
Potential) channels. TRP channels are like physiological canaries in the mine, they sense external stimuli and 
and serve as an early warning system for the organism. TRP channels are found throughout animal species 
including humans, mice, worms and zebrafish (Fig. 6). It has been previously shown that Drosophila TrpA1 
is a thermoreceptor and a critical mediator of nociception in flies and mammals65,66. Prior reports suggest 
Drosophila TRP is required for preserving light response, whereas external noxious heat stimuli (>40 °C) acti-
vates TrpA1, Pyrexia, and Painless channels67–70. The decreased sensitivity to noxious heat observed in our 
heat avoidance assay for Tv1 treated flies suggests it is possible that Tv1 inhibits one of the three heat-activated 
TRP channels. While the Tv1-induced decrease was small, it is a significant finding that Tv1 was peripherally 
administered, therefore Tv1 could serve as a scaffold for designing novel peripherally active antinociceptive 
peptide compounds.
Alternative to Tv1, Tsu1.1 has an orexigenic effect, increasing food consumption by 46%. Using a single-fly 
feeding assay with automated food-consumption tracking allowed us to dissect several aspects of feeding: 
intake, meal count, meal volume and meal duration. Of these, increased meal count appeared to account for 
some of the food intake increase, while meal volume and duration underwent only small changes. This increase 
in feed count does not account for the entire increase in the total consumption. As Tsu1.1 was administered 
by injection, it is possible Tsu1.1 affects the peripheral system of the fly and regulates feeding via a neuroen-
docrinological pathway. Several studies have tried to isolate the effect of neuromodulators on feeding71,72. A 
majority of these neuromodulators have a negative effect on feeding most likely due to disruptions of its motor 
coordination. However, previous studies indicate activation of serotonin, octopamine and dopamine causes an 










































































































































































































Figure 5. Tsu1.1 has effects on food intake by increasing meal frequency. A single-fly feeding assay was used to 
assess total food intake, the average number of meals, meal duration, and meal size over a 6 h period in 5–7 day 
old adult Canton-S males. (A) Flies injected with Tsu1.1 toxin consumed more: +93.3 nl [95 CI 41.6, 141.49], 
g = + 0.55, P = 0.0002, N = 106, 112. (B) Average number of feed bounts where Tsu 1.1 injected flies displayed 
a dramatic increase: ∆feeding bouts +8.64 [95 CI 0.53, 17.23], g = + 0.53, p = 0.047, N = 106, 112. (C, D) Mean 
meal duration and volume per feed showed only minor alterations after injection of Tsu1.1. (E–H) The feeding 
behavioral effect of Tv1 dissected into volume intake, feed count, feed duration and volume per feed. All metrics 
showed only trivial differences. The data represent the mean differences with their 95% CI. Control data are 
depicted in grey, and teretoxin injected-fly data in orange. The numbers below each column denote the effect 
size and sample sizes (N) for each experiment.
www.nature.com/scientificreports/
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Conclusions
We developed a sequence driven, activity-based hybrid approach using venom transcriptomic analysis and 
behavioral characterization in Drosophila melanogaster to identify the bioactivity of venom peptides. Application 
of our method found that Tv1 reduces heat avoidance in fly, suggesting that it has a antinociceptive effect, and 
also indicated that Tsu1.1, a novel teretoxin, modulates feeding behavior. The orexigenic effect of Tsu1.1 arose 
primarily from increased meal frequency, with additional effects from meal duration and volume. Taken together, 
our findings illustrate the utility of Drosophila assays to identify the bioactivity of novel venomics-derived pep-
tides. This phenotypic-screening approach can help to realize the enormous potential that terebrid snail venom 
peptides have as compounds for characterizing cellular physiology, and as candidate therapeutics.
Methods and Materials
Identification of venom peptides. Tsu1.1 was discovered using a transcriptomics and bioinformatics 
pipeline (Fig. 2A). RNA was extracted from the venom duct of Terebra subulata using an RNeasy Micro kit 
(Qiagen). RNA was sequenced with an Illumina HiSeq. 2500 with a multiplexed sample run in a single lane, using 
paired end clustering and 101 × 2 cycle sequencing. Raw reads were first processed on Fast QC to assess the qual-
ity, looking for a phred score ≥30. Low quality reads and adapters were trimmed using Trimmomatic. The de novo 
assembly program Trinity76,77 was used with default parameters to assemble the transcriptome. Once a transcrip-
tome was assembled, EMBOSS’ GetORF78 was used to translate transcripts into Open Reading Frames (ORFs). 
SignalP79 was used to predict signal sequences in the translated ORFs. As teretoxins are secretory peptides, they 
are all associated with a signal sequence that is cleaved off from the mature toxin sequence before envenomation. 
Only those ORFs with signal sequences were analyzed using the basic local algorithm search tool (BLAST)80 and 
an in-house toxin database to identify putative toxins homologous to already known toxins. The sequence of 
Tsu1.1 was found to be SAVEECCENPVCKHTSGCPTT.
Synthesis and oxidative folding of Tv1. As teretoxins are present only in miniscule quantities in the 
venom, a greater quantity of the linear peptide Tv1 was chemically synthesized and purified by previously 
described methods and further oxidatively folded into biologically active form52.
Synthesis and purification of Tsu1.1. Tsu1.1 peptide with a sequence of SAVEECCENPVCKHTSGCPTT 
was synthesized by microwave assisted Fmoc solid–phase peptide synthesis on a CEM Liberty synthesizer using 
standard side chain protection. Following treatment of peptidyl resin with Reagent K [92.5% TFA (Trifluoroacetic 
acid), 2.5% TIS (Triisopropylsilane), 2.5% EDT (1,2 Ethanedithiol) and 2.5% water, 4 h)] and methyl tertiary butyl 
ether (MTBE) precipitation, crude Tsu1.1 checked for purity on Agilent UHPLC machine and eluted using a lin-
ear gradient from 0% to 55% buffer B (80% Acetonitrile with 20% water) in 3.5 min. The identity of synthesized 
peptide was confirmed by molecular mass measurement of purified peptide using 6520 Agilent Q-TOF LC-MS 
(Figs S2 and S3).
Oxidative folding of peptides. A one-step thiol-assisted oxidation was used to prepare folded Tsu1.1 
peptide. The linear peptide (20 µM) was incubated in 0.1 M Tris –HCl, 0.1 M, NaCl, 100 μM EDTA,1 mM GSH 
(reduced glutathione), 1 mM GSSG (oxidized glutathione), pH 7.5. The folding reaction was terminated by acidi-
fication with 8% formic acid at 15 min, 30 min, 1, 2, 3, 4, and 24 h and the folding yield monitored using UHPLC. 
Figure 6. Comparison of TRP channels across the tree of life. Maximum-likelihood phylogeny showing the 
relationship between members of the human TRP-channel superfamily and members of Caenorhabditis elegans 
(worm), Drosophila melanogaster (fly), Danio rerio (zebrafish) and Mus musculus (mouse) TRP channels. 
Drosophila TRP channels associated with pain, such as TrpA1, are also found in humans, mice, and worms.
www.nature.com/scientificreports/
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A preparative scale folding reaction was then conducted at an optimized time of 1 h, and the folded peptide was 
purified using X-Bridge semi-preparative column (waters). Elution was carried out at 5 ml/min with 0% buffer B 
and 100% buffer A for the first 5 min, then increasing buffer B to 35% in 35 min. The purity was confirmed using 
Agilent poroshell UHPLC column and the molecular mass of the oxidized peptide was confirmed by LC-MS. The 
oxidatively folded peptide was used in all the experiments (Figs S4 and S5).
Structure prediction of Tsu1.1. The membrane protein topology and signal peptide prediction was made 
using TOPCONS according to the online instructions81. Model structure was made by using the I-TASSER web 
application82,83. The quality of the model predicted by I-TASSER is verified using two different score systems: 
TM-score and a root mean square deviation. These two scoring systems give an estimate how close the model 
is to the native structure and both of these values are computed from a confidence score (C-Score)82,84. For the 
TM-score a value above 0.5 usually implies a correct topology for the model85,86. The top five high scoring struc-
tures based on C-score from the I-TASSER prediction were superimposed using PyMol.
Multiple sequence alignment. The ConoPrec tool, which is available on the ConoServer website was used 
to identify similar sequences recorded in the ConoServer database87,88. The multiple sequence alignment was 
performed using ClustalW software89.
Fly stocks. All Drosophila melanogaster flies used in the experiments were male Canton-Special aged 5–9 
days at the onset of the experiment. Experimental flies were maintained at 25 °C, 60–70% relative humidity, under 
12:12 h light and dark cycles for 4 to 7 days before the experiment day. If starvation was required, flies were wet 
starved for 24 h before experiments. Wet starvation was performed by keeping flies in a plastic vial with 2% agar.
Teretoxin peptide injection. Concentration of the toxins was determined based on previous studies inves-
tigating the bioactivity of Tv152 which concluded Tv1 to cause partial paralysis in polychaete worms at a con-
centration of 20 μM. A low (20 μM) and high (100 μM) concentration was used for both peptides to obtain a 
range for bioactivity. Injection glass micropipettes (Nanoliter2000 borosilicate glass capillaries, World Precision 
Instruments, Sarasota, FL, U.S.A.) were pulled with a horizontal pipette puller (model P-1000, Sutter Instrument 
Co., Novoto, CA, USA) creating a 11–17 µm wide opening. Freshly pulled needle was blunted by pressing the tip 
through a paper tissue. The injection micropipette was then mounted on a microinjector (Eppendorf Femtojet 
Express 5248) at an injection pressure of 300 kPa. Flies were anesthetized using CO2 and kept sedated throughout 
the entire injection process (maximally for 5 minutes). Anesthesia was maintained by keeping the flies on a pad 
consisting of porous polyethylene. A volume of 0.2 μl was injection by a pulse pressure of 300 kPa under stereom-
icroscope. Typically, the injection site was made intra-thoracically beneath the supraalar bristles (SA1, SA2) and 
the presutural bristle, into the area between between the mesopleura and pteropleura.
Locomotion assay. Flies were tested using an automated video tracking software measuring the distance 
traveled of the flies. Flies were placed in 5 mm × 65 mm glass tubes with food placed at one end of the tube and a 
cotton plug in the other, allowing proper respiration of the flies. The food was allowed to air dry for one hour (to 
prevent flies from drowning in wet bait) before the flies were added. A total of 56 flies were used for each bioactive 
peptide with the same number of control flies injected with the vehicle. To determine phenotypic defects in the 
flies upon injection of Tv1 and Tsu1.1, we examined their activity using an automated video-tracking assay. The 
activity assay employs video tracking to measure the total distance (mm/h/fly) over five consecutive days and 
excludes a 24 h habituation period. The tracking assay measured the long term and short term effects of distance 
travelled and circadian rhythms of the flies. The flies were tracked with computer vision code in LabVIEW using 
standard background subtraction and centroid methods. Behavior data was analyzed and plotted with Python 
using Jupyter and the scikits-bootstrap, seaborn and SciPy packages. Data was collected for five consecutive days 
with the first day subtracted from the assay, a habituation period. The data was then averaged by hour over the 
entire duration of the experiment.
Thermosensation assay. A thermosensation pain assay for adult Drosophila was performed as previously 
described59. Approximately 20 flies, 5 to 7 days old were placed in sealed behavioural chamber (Petri dish meas-
uring 35 mm × 11 mm; Nunclon). Flies were allowed to acclimatize to the environment for 60 min at room tem-
perature. Using a water bath, the bottom of the chamber was heated to 46 °C. The chambers were heated for 4 min 
before they were removed from the water and immobilized flies were counted. The percentage avoidance was cal-
culated by counting the number of flies that failed to avoid the noxious temperature compared to the total number 
of flies in the chamber. The distance from the heated bottom for each fly was not taken into consideration.
Climbing assay. Twenty-four hours before the experiment, male flies were separated from the females and 
transferred to a newly prepared food vial. No more than 20 flies were kept in the same vial. After the habituation 
period, five flies were transferred to 50 ml serological pipette tubes (Falcon, USA) that was cut to 50 mm in length. 
The top and bottom of the tube were sealed with parafilm with three small holes to provide ventilation. Flies were 
habituated to the new environment by lying flat on the surface for one hour at 25 °C. The tube was tapped against 
a hard surface at the beginning of the experiment to place all the flies at the bottom of the vial. The time for each 
fly to reach the top marked point was recorded. Any flies that could not reach the top mark within 60 seconds 
were marked as failure to climb. Climbing index was calculated as a range from 0 to 1 for the number of flies that 
managed to reach the top mark within a certain time. A failure to reach the top mark gave them a score of 0 and a 
success, a score of 1. An average for all flies was calculated for all the trials.
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Feeding assay. Male flies were anesthetized by cooling and placed in chambers for the feeding assay, 
where capillaries delivered liquid food (5% sucrose, 10% red colour food dye in deionized water) to the fly. 
The experiment was conducted within an incubator that was maintained at 22 °C64. The individual toxins were 
tested on different days; all experimental conditions were kept constant in between and during each experi-
ment with respect to: temperature, humidity, circadian time, days after eclosion and the sex of the flies. The 
level of the fluid was monitored using video tracking for 6 h. Each capillary was accessible by a single fly kept in 
a 12 mm × 12 mm × 2 mm chamber cut from acrylic. The food intake assays for the individual fly lines were not 
performed concurrently but with identical duration, start time for the experiment, age and sex of flies, tempera-
ture and starvation time. For experiments involving starvation, flies were wet starved for 24 h before the start of 
the experiment; during wet starvation, flies were deprived of food but not water in a vial containing 1% agarose 
dissolved in deionized water. Different sets of flies were used for the vehicle and toxin injections, as well as for the 
fed and the food-deprivation.
Determination of effects on activity and motor coordination. Flies aged for 5–7 days after eclosion 
were anesthetized using CO2 and single flies were transferred to glass tube (5 mm × 665 mm) containing food in 
one end and sealed with a plastic cap with the opposing end sealed with a cotton wool plug. Standard fly food 
was used for both the experimental and negative control. One hour prior to the start of the experiment flies were 
anaesthetized and injected with the toxin. The flies were allowed to recover for one hour before being transferred 
to the glass tubes and inserted into the arena within a light and temperature regulated incubator. The temperature 
was set to 22 °C with a 60–70% relative humidity, under 12:12 h light and dark cycles. When comparing exper-
imental and control flies, they were distributed with 56 control flies and 56 experimental flies on each side of 
the arena. The flies were habituated for 24 h before commencing the experiment. The activity was automatically 
measured by tracking the path of each individual fly by means of video tracking and calculated as the numbers 
of crosses over the midline of the glass tube along with distance travelled. To assess sleep duration a threshold for 
sleep was used and is according to previously published protocols for sleep assessment in Drosophila: a period of 
inactivity lasting for at least five consecutive minutes90 sleep duration was measured as the cumulative amount 
of sleep in a 24 h period measured in minutes. As baseline activity of control animals was susceptible to change 
between experiments over time, each peptide was tested in otherwise identical animals assayed in parallel.
Statistics and analysis. The data was analyzed with estimation methods to calculate mean, mean differ-
ences, confidence intervals91, and Hedges’ g where appropriate60. Data are presented for each individual fly as 
well as the mean difference in estimation plots. 95% confidence intervals for the mean differences were calculated 
using bootstrap methods (resampled 5000 times, bias-corrected, and accelerated) and are displayed with the 
bootstrap distribution of the mean. Effect size was measured using Hedges’ g and are as per standard practice 
referred to as either ‘trivial’ (g < 0.2), ‘small’ (0.2 < g < 0.5), ‘moderate’ (0.5 < g < 0.8) or ‘large’ (g > 0.8)92. Hedges’ 
is a quantitative measurement for the difference between means, and is an indication of how much two groups 
differ from each other where a Hedges’ g of 1 shows that the two groups differ by 1 standard deviation. Commonly 
used significance testing and power calculations were avoided following recommended practice92,93 the Mann 
Whitney U statistic was used to calculate P values for pro forma reporting exclusively. To indicate estimate pre-
cision, 95% confidence intervals (95CI) were calculated using bootstrap methods and reported in text and/or as 
error bars92. The behavioral data are presented as mean-difference estimation plots. Confidence intervals were 
bias-corrected and accelerated, and are displayed with the bootstrap distribution of the mean; resampling was 
performed 5,000 times. While P values reported are related to two-tailed Student’s t-test statistics, significance 
testing was not performed91.
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